Nick Yeo
About
Nick Yeo is from Barns Green, England, United Kingdom. Nick works in the following industries: "Medical Device", and "Pharmaceuticals". Nick is currently Chief Executive Officer at Veryan Medical Ltd, an Otsuka Medical Devices company, located in Horsham, UK and Galway, Ireland. In Nick's previous role as a Clinical Study Director at Light Sciences Oncology, Inc., Nick worked in until Oct 2011. Prior to joining Light Sciences Oncology, Inc., Nick was a President, InLumena Vascular at Light Sciences Oncology, Inc. and held the position of President, InLumena Vascular. Prior to that, Nick was a President at Vascular Reconditioning, Inc. from Nov 2004 to Dec 2006. Nick started working as VP, Strategic Business Development at Light Sciences Corporation in Apr 2001. From Sep 1999 to Mar 2001, Nick was VP Oncology Product Development at Light Sciences Corporation. Prior to that, Nick was a Managing Director at Scotia QuantaNova plc from Sep 1995 to Sep 1999. Nick started working as Senior Director, European Marketing at Gensia Europe Limited in Jan 1992.
Go to finalscout.com and type Nick Yeo's name into the search box for a free email address. FinalScout is a professional database with more than 500 million business professionals and 200 million company executives.
Nick Yeo's current jobs
Veryan Medical has pioneered the next generation of nitinol self-expanding stent technology featuring patent-protected, 3D helical curvature in the stent design to mimic natural vascular anatomy. This unique stent design improves biomechanical performance to reduce stent fracture and mobilizes Swirling Flow in blood moving through the stent to reduce re-narrowing of the treated artery that can lead to need for re-intervention. The BioMimics 3D Stent System is CE Marked and commercialized in Europe for interventional use in treatment of peripheral arterial disease of the lower limb. US Premarket Approval was granted by FDA in October 2018 and by Japanese PMDA in December 2019.
Nick Yeo's past jobs
Leadership of clinical Phase 3 IND study in metastatic colorectal cancer at 50+ hospitals across Europe, Russia, Ukraine and India. Responsible for coordination of multiple clinical research, data and imaging vendors. Management of relationships with investigational staff across all enrolling sites. Achieved target enrollment of 450 patients.
Responsible for all preclinical and technology development activities on innovative interventional cardiovascular technology in preparation for first clinical experience in man, including regulatory interface with FDA. Formulated clinical development strategy and protocol design in conjunction with consulting cardiologist and key opinion leaders. Developed extensive network of academic interventional cardiology support for development plans in 3 priority development areas: (i) prevention of restenosis following SFA intervention in patients with peripheral arterial disease; (ii) stabilization of atherosclerotic plaque in patients with coronary artery disease; (iii) prevention of vascular access graft dysfunction. Led venture capital fund-raising and corporate partnering activities
Developed technology strategy, business plan and authored the VRI Series A Private Placement Memorandum to raise capital to spin out VRI from Light Sciences LLC and fund development operations. Led activities to secure technical and commercial validation of VRI’s value proposition in interventional cardiology. Negotiated a term sheet with a global medical device company. Implemented a virtual operating strategy and secured further angel investment to maintain program momentum during fund-raising for these activities. Developed a world-class scientific advisory panel and specialist consulting support to add credibility and gain scientific scrutiny of the Company’s intended development programs
Provided leadership for all partnering activities (oncology, ophthalmology and cardiovascular medicine) to increase business value and create funding opportunities for non-oncology assets. Conceived a novel hypothesis for use of the Company’s core technology in atherosclerotic disease
Program Leader with responsibility for international development of the Light Sciences' Light Infusion Technology (drug|device combination) for procedural ablation of solid tumours. Led a multidisciplinary team to complete all preclinical development and regulatory activities to secure US IND clearance for clinical start. The System entered clinic trials in March 2001.
Led development of an organization to transition an early stage preclinical research concept through to clinical development for treatment of head and neck cancer in US, EU and Asia. Provided leadership of all clinical activities being undertaken by internal staff and CROs. Led pre-IND / EOP2 meetings with FDA CDER/CDRH staff. Secured worldwide development and commercialisation deals - Foscan® was subsequently approved by EMEA in July 2001.
Led the start-up of Gensia’s commercial operations in Europe in cardiology, cardiothoracic surgery and general surgery sectors Negotiated distribution agreements in major European markets and personally recruited and managed sales teams in UK, France and Germany. Launched GenESA System (drug with computerised delivery system providing feedback control used in diagnosis of coronary artery disease) in cardiology sector in UK, Germany and Benelux
Operational responsibility for £30 million UK pharmaceutical business with 130 staff [sales revenue split: 85% GP / 15% hospital] Launched NCE, brand extension and in-licensed products. Led successful product pricing negotiations with UK Dept of Health. Introduced innovative promotional approaches and worked with various communication agencies to enhance recognition and adoption of new company values during a period of significant organisational change in the lead-up to the merger with Sanofi.